<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1114">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146648</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY-21-00837</org_study_id>
    <nct_id>NCT05146648</nct_id>
  </id_info>
  <brief_title>Gondola Mechanism of Action</brief_title>
  <official_title>Mechanism of Action for Effects From Automated Mechanical Peripheral Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the clinical, functional and neurophysiological effects of&#xD;
      automated mechanical peripheral stimulation (AMPS) via the Gondola device administered to&#xD;
      patients with chronic stroke, cerebral palsy and Parkinson's Disease. Results will be&#xD;
      collected using standardized outcome measures and a transcranial magnetic stimulation&#xD;
      assessment protocol including electrical stimulation and electromyographic recording.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The working hypothesis for this pre-post intervention study is that one session of AMPS will&#xD;
      increase voluntary motor drive of the plantar-flexors (soleus) muscle. The primary outcome&#xD;
      measure will be maximum voluntary contraction (MVC) of the soleus (measured by&#xD;
      electromyography, EMG); the secondary outcome will be the MVC of the antagonist muscle, the&#xD;
      tibialis anterior. Data will be collected before the first session compared to directly&#xD;
      after. The same measures in sham-stimulated and healthy volunteers will serve as controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Twenty adult individuals in the chronic phase of stroke, 20 people with cerebral palsy, 20 with Parkinson's Disease (intermediate stage) and 20 healthy volunteers will be randomized to receive sham or real AMPS intervention.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>A blinded evaluator will collect all the demographic (age, gender, time since injury, injury type), clinical and functional data of the participants. The investigator performing transcranial magnetic stimulation assessments will also be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Soleus MVC</measure>
    <time_frame>pre and post-AMPS (baseline and 2 minutes)</time_frame>
    <description>maximum voluntary contraction of the soleus muscle (measured by EMG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Tibialis anterior MVC</measure>
    <time_frame>pre and post-AMPS (baseline and 2 minutes)</time_frame>
    <description>maximum voluntary contraction of tibialis anterior (measured by EMG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 10 meter walk test</measure>
    <time_frame>pre and post-AMPS (baseline and 2 minutes)</time_frame>
    <description>self-selected pace to determine gait speed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Stroke</condition>
  <condition>Cerebral Palsy</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Real AMPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMPS therapy consists of mechanical stimulations applied to two specific points on both feet: the tip of the big toe (hallux) and the first metatarsal joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham AMPS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>AMPS therapy applied to two non-specific points on both feet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gondola AMPS</intervention_name>
    <description>One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the four stimulation points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.</description>
    <arm_group_label>Real AMPS</arm_group_label>
    <arm_group_label>Sham AMPS</arm_group_label>
    <other_name>Automated Mechanical Peripheral Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 to 80;&#xD;
&#xD;
          -  chronic stroke lesion &gt;6 months after a cerebrovascular accident OR diagnosis of&#xD;
             cerebral palsy OR Parkinson's Disease;&#xD;
&#xD;
          -  presence of some degree of motor function in the ankle flexor (Soleus motor power &gt;1);&#xD;
&#xD;
          -  able to ambulate 10 meters without physical assistance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medically unstable condition;&#xD;
&#xD;
          -  presence of other concurrent neurological illness;&#xD;
&#xD;
          -  cognitive impairment (Montreal Cognitive Assessment score &lt;23);&#xD;
&#xD;
          -  presence of any potential TMS risk factor: damaged skin at the site of stimulation;&#xD;
&#xD;
          -  presence of an electrically, magnetically or mechanically activated implant, an&#xD;
             intracerebral vascular clip, or any other electrically sensitive support system;&#xD;
&#xD;
          -  family history of medication-resistant epilepsy;&#xD;
&#xD;
          -  past history of seizures or unexplained spells of loss of consciousness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Rozanski</last_name>
    <role>Study Director</role>
    <affiliation>MOUNT SINAI HOSPITAL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Putrino, PT, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leila Nasr</last_name>
    <phone>212-824-8369</phone>
    <email>leila.nasr@mountsinai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abilities Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Leila Nasr</last_name>
      <phone>212-824-8369</phone>
      <email>leila.nasr@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>David Putrino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>David Putrino</investigator_full_name>
    <investigator_title>Director of Rehabilitation Innovation for the Mount Sinai Health System; Associate Professor, Rehabilitation Medicine</investigator_title>
  </responsible_party>
  <keyword>ambulation</keyword>
  <keyword>sensory stimulation</keyword>
  <keyword>mobility</keyword>
  <keyword>neurological disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not applicable to study aims</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

